CONNECTA Therapeutics and the Parc Taulí Research and Innovation Institute (I3PT), members of CataloniaBio & HealthTech, together with the Centre for Genomic Regulation (CRG) and the Hospital del Mar Research Institute have secured 2.7 million euros in funding from the Ministry of Science, Innovation, and Universities of Spain and the European Union, through the Next Generation EU program, to initiate Phase IIa clinical trials of the drug CTH120 for the treatment of fragile X syndrome (FXS).
The funding from the competitive call "Public-Private Collaboration Projects" complements the private investment of investors in CONNECTA Therapeutics, including Inveready, also member of CataloniaBio & HealthTech, CDTI Invierte and Prous Institute for Biomedical Research.
CTH120 is an innovative therapy designed using artificial intelligence techniques that acts as a neuroplasticity modulator. Phase I clinical trials for CTH120 are currently being completed at the Hospital del Mar Research Institute in Barcelona, led by Dr. Rafael de la Torre and Dr. Ana Aldea as principal researchers.
The forecast is to have the results of the Phase I clinical trial during the first semester of this year and to be able to start Phase IIa in the first semester of 2025. In this new phase, I3PT, with Dr. Ana Roche as the principal investigator, joins as a strategic partner along with the CRG and the Research Institute of Hospital del Mar. During the project, specific biomarkers will also be identified to facilitate the assessment of treatment response, an activity led by Dr. Mara Dierssen at the CRG.
"We are pleased to announce this news a few days before the celebration of Rare Disease Day, the therapies for which are a major challenge for public health. This funding from the Ministry of Science, Innovation and Universities allows us to progress in the clinical development of a specific treatment for fragile X syndrome with prestigious international centers and researchers in the field of neuroscience in the Barcelona area," comments Jordi Fàbrega, CEO and co-founder of CONNECTA Therapeutics.
Comments